Strategic Science & Technologies

8 articles about Strategic Science & Technologies

• Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

  11/1/2023

  Daré Bioscience, Inc., a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC, a Cambridge, MA based novel topical drug delivery company, announced additional positive findings based on further analyses of data from the exploratory Phase 2b RESPOND study that evaluated Sildenafil Cream, 3.6% in women with female sexual arousal disorder.

• Daré Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine Society of North America Conference

  10/28/2019

  Daré Bioscience, Inc., a leader in women’s health innovation, and Strategic Science & Technologies, LLC, a Cambridge, MA based novel topical drug delivery company, announced a poster presentation at the Sexual Medicine Society of North America 20th Annual Fall Scientific Meeting, which took place in Nashville, Tennessee, October 24-27, 2019.

• Strategic Science & Technologies Initiates Phase II Study To Evaluate Topical Sildenafil In Women With Female Sexual Arousal Disorder

  10/28/2015

• Strategic Science & Technologies Initiates Phase II Study To Evaluate Topical Sildenafil In Men With Erectile Dysfunction

  6/17/2015

• Strategic Science & Technologies Announces Completion Of Its Phase 1 Clinical Trial For SST-6007, A First-In-Class Topical Sildenafil Cream, To Treat Female Sexual Arousal Disorder

  5/14/2015

• Strategic Science & Technologies Initiates Phase 1 Study To Evaluate Topical Sildenafil In Women With Female Sexual Arousal Disorder

  2/9/2015

• Strategic Science & Technologies Signs Partnership Agreement With A Leading Global Pharmaceutical Company For U.S. Commercial Rights To Topical Ibuprofen

  12/18/2014

• Strategic Science & Technologies Announces Completion Of Its Phase 1 Clinical Trial For SST-6006, A First-In-Class Topical Sildenafil Product Candidate Being Developed For The Treatment Of Erectile Dysfunction In Men

  5/15/2014